Skip to content Skip to footer
Subscribe Now
VIEWPOINTS_Matthew G. Fishler_2023
VIEWPOINTS

Matthew G. Fishler Shares the Highlights of AVEIR DR, the World’s First Dual-Chamber Leadless Pacemaker System

Shots:  Matthew G. Fishler, Chief Engineer and Director of Product Development Abbott’s Cardiac Rythm Management Business, in an insightful conversation with PharmaShots   Matthew shares the highlights of the recently approved AVEIR Dr, the world’s first dual-chamber leadless pacemaker system for patients with slower-than-normal or abnormal heart rhythms   Equipped with i2i™ communication technology, AVIER DR eliminates…
November 20, 2023

Read more

VIEWPOINTS_Grant Kim_2023
VIEWPOINTS

Grant Kim Shares His Views from the Data Showing the World’s First Dual-Chamber Leadless Pacemaker Study Achieving All Three Primary Endpoints

Shots: Grant started by highlighting the characteristics of the AVEIR DR leadless pacemaker and this pacemaker is an effective treatment for people with slower-than-normal heart rhythms He discussed the AVEIR™ DR i2i™ IDE study's design and outcomes, which assessed the safety and performance of the world's first dual-chamber leadless pacemaker. The study effectively met all…
September 19, 2023

Read more

VIEWPOINTS_Dr. Christopher Piorkowski_2023
VIEWPOINTS

Dr. Christopher Piorkowski Shares His Views on the US FDA Approval of TactiFlex Ablation Catheter to Treat Abnormal Heart Rhythm

Shots: Christopher started by highlighting the working of the TactiFlex Ablation Catheter and how it can be used for the treatment of patients with Atrial Fibrillation He also talked about the study design and the key findings from the TactiFlex AF IDE trial. He later gave a comparative view of the TactiFlex catheter vs. conventional…
September 11, 2023

Read more

VIEWPOINTS_Dr. Beth McQuiston_2023
VIEWPOINTS

Dr. Beth McQuiston Shares her Views on the US FDA Clearance of the First Concussion Blood Test Available for Lab Instruments

Shots: Dr. Beth discussed traumatic brain injuries (TBIs) and the new TBI blood test by Abbott. She told PharmaShots how this blood test measures specific biomarkers, offering objective results within 12 hours, and aiding in evaluating suspected mild TBIs She also talked about how Abbott’s Alinity i lab technology facilitates swift testing, complementing Abbott's i-STAT…
August 21, 2023

Read more

VIEWPOINTS_Mary Rodgers_2023
VIEWPOINTS

Mary Rodgers, Principal Research Scientist at Abbott Shares Insights on its Partnership with CLIMADE Consortium to Predict Disease Outbreaks Caused by Climate Change

Shots: Mary talked about Abbott's partnership Climate Amplified Disease and Epidemics (CLIMADE) consortium will use data science to predict, track and control diseases that may be amplified by climate change She then spoke about how Abbott and its partners in the Abbott Pandemic Defense Coalition will provide viral sequencing and testing data as part of…
August 3, 2023

Read more

Viewpoints_Erika Ross
VIEWPOINTS

Erika Ross, Director of Clinical & Applied Research at Abbott Shares Insights on FDA Breakthrough Device Designation to Explore its DBS System to Treat Treatment-Resistant Depression

Shots:  Erika spoke about the FDA Breakthrough Device Designation received by Abbott to investigate its deep brain stimulation (DBS) system to treat treatment-resistant depression (TRD) Erika also talked about how NeuroSphere Virtual Clinic is compatible with the  deep brain stimulation (DBS) system  The interview gives an understanding of Abbott’s vision to bring life-changing technologies in…
October 5, 2022

Read more

Load more